Acumen director awarded RSUs and stock options
Acumen Pharmaceuticals director Kimberlee C. Drapkin received new equity awards.
Rhea-AI Filing Summary
Acumen Pharmaceuticals director Kimberlee C. Drapkin received new equity awards. She was granted 35,500 restricted stock units, each representing a right to receive one share of common stock. These RSUs vest in full on the earlier of the first anniversary of the grant date or the 2027 annual stockholder meeting, subject to continued service.
She also received stock options covering 53,250 shares at an exercise price of $2.29 per share, expiring on June 3, 2036, with the same vesting schedule. Following these awards, she directly holds 48,300 shares of Acumen common stock. The transactions reflect compensation-related grants rather than open-market purchases or sales.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 88,750 shares
Grant/Award
2 txns
Insider
Drapkin Kimberlee C
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 53,250 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 35,500 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 53,250 contracts (Direct);
Common Stock — 48,300 shares (Direct)
Footnotes (2)
- F1. Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
- F2. The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
Key Figures
RSU award: 35,500 units
Stock options granted: 53,250 options
Option exercise price: $2.29 per share
+2 more
5 metrics
RSU award
35,500 units
Restricted stock units granted to director on June 3, 2026
Stock options granted
53,250 options
Stock Option (right to buy) granted on June 3, 2026
Option exercise price
$2.29 per share
Exercise price for 53,250 stock options
Option expiration
June 3, 2036
Expiration date of granted stock options
Shares held after grant
48,300 shares
Total common stock directly held after transactions
Key Terms
restricted stock unit ("RSU"), Stock Option (right to buy), vest in full, annual stockholder meeting, +1 more
5 terms
restricted stock unit ("RSU") financial
"Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right..."
Stock Option (right to buy) financial
"Stock Option (right to buy) reported as a derivative security transaction..."
vest in full financial
"The RSUs will vest in full on the earlier of the first anniversary of the date of grant..."
annual stockholder meeting financial
"on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting..."
An annual stockholder meeting is a yearly gathering where a company's owners (shareholders) receive updates on performance, vote on key issues like board members, executive pay and major corporate plans, and ask questions of management. Think of it as a company town hall where choices about oversight and direction are decided; outcomes can affect management accountability, corporate strategy and ultimately the value and risks of investors’ shares.
exercise price financial
"conversion or exercise price for the stock option is 2.2900 per share..."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did Acumen (ABOS) director Kimberlee Drapkin receive?
Kimberlee Drapkin received 35,500 restricted stock units and stock options for 53,250 shares. The RSUs convert into common stock, and the options allow future purchases at a fixed price, aligning her compensation with Acumen Pharmaceuticals’ long-term performance.
When do Kimberlee Drapkin’s new Acumen (ABOS) RSUs and options vest?
Both the RSUs and options vest in full on the earlier of the first anniversary of the grant date or the 2027 annual stockholder meeting. Vesting requires Drapkin’s continuous service with Acumen Pharmaceuticals through that vesting date.
What is the exercise price and expiration for Drapkin’s Acumen (ABOS) stock options?
The granted stock options cover 53,250 shares of Acumen common stock at an exercise price of $2.29 per share. These options expire on June 3, 2036, giving a long-dated opportunity to buy shares at that fixed price if vested.
Are Kimberlee Drapkin’s recent Acumen (ABOS) transactions open-market buys or compensation?
The transactions are compensation-related grants, not open-market trades. They include a restricted stock unit award and a stock option grant, both issued at no cash cost to Drapkin, subject to vesting and continuous service requirements with Acumen Pharmaceuticals.
AI-generated analysis. How Rhea-AI works. Not financial advice.
